DE69633332T2 - Alpha-substituierte pyrimidin-thioalkylderivate und alkylether als inhibitoren viraler reverser transkriptfase - Google Patents

Alpha-substituierte pyrimidin-thioalkylderivate und alkylether als inhibitoren viraler reverser transkriptfase Download PDF

Info

Publication number
DE69633332T2
DE69633332T2 DE69633332T DE69633332T DE69633332T2 DE 69633332 T2 DE69633332 T2 DE 69633332T2 DE 69633332 T DE69633332 T DE 69633332T DE 69633332 T DE69633332 T DE 69633332T DE 69633332 T2 DE69633332 T2 DE 69633332T2
Authority
DE
Germany
Prior art keywords
mmol
amino
chloro
ethyl
thiopyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633332T
Other languages
German (de)
English (en)
Other versions
DE69633332D1 (de
Inventor
A. Richard NUGENT
G. Donn WISHKA
J. Gary CLEEK
R. David GRABER
Thomas Stephen SCHLACHTER
J. Michael MURPHY
Joel Morris
C. Richard THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of DE69633332D1 publication Critical patent/DE69633332D1/de
Publication of DE69633332T2 publication Critical patent/DE69633332T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69633332T 1995-05-08 1996-05-03 Alpha-substituierte pyrimidin-thioalkylderivate und alkylether als inhibitoren viraler reverser transkriptfase Expired - Fee Related DE69633332T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08
US436708 1995-05-08
PCT/US1996/006119 WO1996035678A1 (en) 1995-05-08 1996-05-03 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

Publications (2)

Publication Number Publication Date
DE69633332D1 DE69633332D1 (de) 2004-10-14
DE69633332T2 true DE69633332T2 (de) 2005-09-22

Family

ID=23733510

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633332T Expired - Fee Related DE69633332T2 (de) 1995-05-08 1996-05-03 Alpha-substituierte pyrimidin-thioalkylderivate und alkylether als inhibitoren viraler reverser transkriptfase

Country Status (26)

Country Link
US (1) US6043248A (enExample)
EP (2) EP1449835A3 (enExample)
JP (1) JPH11507017A (enExample)
KR (1) KR100445498B1 (enExample)
CN (2) CN1152022C (enExample)
AT (1) ATE275550T1 (enExample)
AU (1) AU712404B2 (enExample)
BR (1) BR9608265A (enExample)
CA (1) CA2216099C (enExample)
CZ (1) CZ293135B6 (enExample)
DE (1) DE69633332T2 (enExample)
ES (1) ES2227586T3 (enExample)
GE (1) GEP20002297B (enExample)
HU (1) HUP9801995A3 (enExample)
IL (1) IL118075A0 (enExample)
MX (1) MX9708582A (enExample)
NO (1) NO310287B1 (enExample)
NZ (1) NZ307089A (enExample)
PL (1) PL323240A1 (enExample)
PT (1) PT824524E (enExample)
RU (1) RU2167155C2 (enExample)
SK (1) SK150297A3 (enExample)
TW (1) TW450962B (enExample)
UA (1) UA56992C2 (enExample)
WO (1) WO1996035678A1 (enExample)
ZA (1) ZA963281B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034167A1 (en) * 1997-09-25 2000-09-13 PHARMACIA & UPJOHN COMPANY Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
US6111111A (en) * 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
DK1858861T3 (da) * 2005-03-04 2010-11-08 Tibotec Pharm Ltd HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用
WO2011103559A1 (en) 2010-02-22 2011-08-25 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103140474A (zh) * 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
PH12022550783A1 (en) * 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
CA3167672A1 (en) * 2020-01-20 2021-07-29 Agrematch Ltd. Compositions for crop protection
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
JP2025504415A (ja) * 2022-01-12 2025-02-12 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
US3940240A (en) * 1974-07-11 1976-02-24 Ina Seito Co., Ltd. Baking method and kiln for tile
DE3369514D1 (en) * 1983-05-05 1987-03-05 Heumann Ludwig & Co Gmbh Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
MX9203454A (es) * 1989-12-28 1992-08-01 Upjohn Co Compuestos anti sida diaromaticos substituidos.
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
KR100236808B1 (ko) * 1991-07-03 2000-02-01 로렌스 티. 마이젠헬더 에이즈 치료약제로서의 치환된 인돌
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
EP0720607A1 (en) * 1993-09-17 1996-07-10 PHARMACIA & UPJOHN COMPANY Substituted tetronic acids useful for treating hiv and other retroviruses
EP0728130A1 (en) * 1993-11-12 1996-08-28 PHARMACIA & UPJOHN COMPANY Pyrimidine-thioalkyl and alkylether compounds
WO1995029897A1 (en) * 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
PL318298A1 (en) * 1994-07-20 1997-06-09 Byk Gulden Lomberg Chem Fab Thiopyridil compounds for fighting against heliobacter

Also Published As

Publication number Publication date
KR19990008400A (ko) 1999-01-25
AU5635396A (en) 1996-11-29
NZ307089A (en) 1999-07-29
NO310287B1 (no) 2001-06-18
BR9608265A (pt) 1999-02-02
KR100445498B1 (ko) 2004-11-16
EP0824524A1 (en) 1998-02-25
PT824524E (pt) 2005-01-31
US6043248A (en) 2000-03-28
ES2227586T3 (es) 2005-04-01
GEP20002297B (en) 2000-11-25
EP0824524B1 (en) 2004-09-08
HUP9801995A2 (hu) 1999-03-29
TW450962B (en) 2001-08-21
NO975129L (no) 1998-01-07
AU712404B2 (en) 1999-11-04
WO1996035678A1 (en) 1996-11-14
EP1449835A3 (en) 2004-09-15
JPH11507017A (ja) 1999-06-22
IL118075A0 (en) 1996-08-04
UA56992C2 (uk) 2003-06-16
RU2167155C2 (ru) 2001-05-20
ATE275550T1 (de) 2004-09-15
ZA963281B (en) 1997-10-24
CN1535958A (zh) 2004-10-13
CN1183773A (zh) 1998-06-03
CA2216099A1 (en) 1996-11-14
CZ349197A3 (cs) 1998-04-15
MX9708582A (es) 1998-02-28
NO975129D0 (no) 1997-11-07
HK1009446A1 (en) 1999-09-10
SK150297A3 (en) 1998-10-07
EP1449835A2 (en) 2004-08-25
PL323240A1 (en) 1998-03-16
CN1152022C (zh) 2004-06-02
CA2216099C (en) 2005-09-13
CZ293135B6 (cs) 2004-02-18
HUP9801995A3 (en) 1999-04-28
DE69633332D1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
EP0824524B1 (en) Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase
EP0298452B1 (de) In 4-Stellung durch Aryl oder N-Heteroaryl substituierte 2H-1-Benzopyran-Derivate
DE69217112T2 (de) Phenyl-pyrazolidinone als Bronchodilatatoren und entzündungshemmende Mittel
DE69304243T2 (de) Chinolin-Verbindungen als Angiotensin-II-Antagoniste
EP0510526A1 (de) Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide
DE60120138T2 (de) Amid-verbindungen und deren verwendung
DE69727915T2 (de) Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten
DE2406930A1 (de) Neue heterocyclische verbindungen und verfahren zu ihrer herstellung
DD146293A5 (de) Verfahren zur herstellung von 5-(4-pyridyl)-6-(4-fluorphenyl)-2,3-dihydroimidazo eckige klammer auf 2,1-b eckige klammer zu thiazol,seiner salze und seiner oxide
EP0266558A2 (de) 5-Alkylbenzimidazole, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DD213920A5 (de) Verfahren zur herstellung von dihydropyridinen
EP0009206A2 (de) Fluorhaltige 1,4-Dihydropyridine, diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung
EP0011142A1 (de) Pyrido (2,1-b) chinazolinon-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69311887T2 (de) Morphinan-O-Arylether
DE2009408A1 (de) 5-Pyridyl-2-imidazolone
DE60101224T2 (de) Hydroxamsäure-Derivate
DE10237883A1 (de) Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
CH636862A5 (de) In 2-stellung substituierte 5-hydroxy-1h-imidazol-4-carboxamidderivate, ihre salze und verfahren zu ihrer herstellung.
DE3343922A1 (de) Gewisse substituierte pyrazolochinoline, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und ihre therapeutische anwendung
DE4130933A1 (de) Neue (beta)-carbolinderivate, deren herstellung und verwendung in arzneimitteln
DE69628750T2 (de) Neue antivirale, homocarbozklische nukleosidderivate von substituierten pyrimidindionen, verfahren zu ihrer herstellung und zusammensetzungen, die diese als aktiven bestandteil enthalten
DE4120322A1 (de) Aminomethyl-substituierte 2,3-dihydropyrano(2,3-b)pyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE19536378A1 (de) Heterocyclische Aryl-, Alkyl- und Cycloalkylessigsäureamide
EP0657459A1 (de) Neue Thienothiazinderivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Antiinflammatorikum und Analgeticum
DE69413545T2 (de) Thiazole mit antiviraler wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee